EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation

Mikołaj Stańczak, Robert Jarema

Romanian Journal of Preventive Medicine · 17.11.2026 · 4 (4) · 17

DOI: 10.3390/rjpm4040017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Romanian Journal of Preventive Medicine, online erschienen am 17.11.2026. Verfasst von Mikołaj Stańczak und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mechanistic target of rapamycin (mTOR) is an atypical serine/threonine kinase of the phosphatidylinositol 3-kinase-related kinase family that couples nutrient and growth-factor availability to the decision between anabolism and catabolic recycling. Rather than cataloguing the field, this review is organised around a single argument: the therapeutic behaviour of mTOR-directed drugs is governed less by the potency with which they inhibit the kinase than by which complex is rate-limiting in which tissue, and most translational disappointments to date are explained by that distinction. We first summarise the molecular architecture of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), including recent structural work showing that mTORC2 selects Akt through distal docking on mSin1 some 75 Å from the catalytic site rather than through a local sequence motif. We then treat the lysosomal nutrient-sensing module, the growth-factor and energy inputs converging on TSC–Rheb, and the downstream output arms, explicitly separating findings that are well established from those that remain contested the relative physiological weight of the competing leucine-sensing mechanisms being the clearest example. A dedicated analysis of tissue-specific physiology shows that mTORC1 and mTORC2 have opposing consequences in liver, adipose tissue and pancreatic β-cells, which accounts mechanistically for hyperglycaemia, dyslipidaemia and new-onset diabetes during rapalog therapy, and predicts the therapeutic index of mTORC1-selective bi-steric agents. We add a treatment of circadian regulation of mTOR, absent from most pathway reviews, and update the clinical sections with the completed phase 1 trial of RMC-5552 and a critical appraisal of the PEARL, RTB101 and TRIIM studies. Human trials of mTOR inhibition differ so profoundly in population, compound selectivity, dose, schedule and endpoint that their apparently discordant results are largely reconcilable; we set out the specific design features a definitive geroscience trial would require. We conclude that partial, intermittent and complex-selective inhibition not maximal target engagement is the rational objective of mTOR pharmacology.

Zitieren

APA

Stańczak, M., & Jarema, R. (2026). The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation. Romanian Journal of Preventive Medicine, 4(4), 17. https://doi.org/10.3390/rjpm4040017

Vancouver

Stańczak M, Jarema R. The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation. Romanian Journal of Preventive Medicine. 2026;4(4):17. doi:10.3390/rjpm4040017

BibTeX
@article{Staczak2026,
  author = {Stańczak, Mikołaj and Jarema, Robert},
  title = {The mTOR Signalling Pathway: A Critical Review of Molecular Mechanism, Tissue-Specific Physiology and Clinical Translation},
  journal = {Romanian Journal of Preventive Medicine},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {17},
  doi = {10.3390/rjpm4040017}
}
Kostenlos starten →